Brae­burn Phar­ma files for $150M IPO; Tiziana in-li­cens­es Novim­mune an­ti­body

• Brae­burn Phar­ma­ceu­ti­cals, which mar­kets and de­vel­ops treat­ments for opi­oid ad­dic­tion, has filed for a $150 mil­lion IPO. The of­fer­ing notes that Ap­ple Tree Part­ners has agreed to buy $40 mil­lion in stock. Here’s the S-1.

• The UK’s Tiziana Life Sci­ences has bagged a glob­al li­cense for the IL-6R an­ti­body NI-1201 from Novim­mune. The com­pa­nies did not spell out the fi­nan­cial terms of the deal. “We view NI-1201 as a po­ten­tial game-chang­er for ad­dress­ing the high un­met need of au­toim­mune and in­flam­ma­to­ry dis­eases” com­ment­ed Gabriele Cer­rone, Chair­man of Tiziana Life Sci­ences. “The ac­qui­si­tion of NI-1201 not on­ly strength­ens our busi­ness strat­e­gy of de­vel­op­ing nov­el ful­ly hu­man mAbs to treat life-threat­en­ing in­flam­ma­to­ry dis­eases such as non-al­co­holic steato­hep­ati­tis (NASH) and rheuma­toid arthri­tis, but ex­pands our po­ten­tial to lever­age the pi­o­neer­ing work we are do­ing with foralum­ab, the oral an­ti-CD3 mAb to treat au­toim­mune and in­flam­ma­to­ry dis­eases.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.